Tags

Type your tag names separated by a space and hit enter

The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Hepatogastroenterology 2014; 61(132):1008-13H

Abstract

BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine.

METHODOLOGY

Colorectal cancer patients scheduled for capecitabine chemotherapy as adjuvant setting were randomly assigned to with or without concurrent oral pyridoxine (60 mg/d) groups. Patients were monitored whether being a development of National Cancer Institute Common Toxicity Criteria grade 2 or worse HFS until chemotherapy ended.

RESULTS

Sixty patients were enrolled in this study. Relative dose intensity was 89.5% in total. The median number of chemotherapy cycles to grade 2 or worse HFS was four in both groups. Grade 2 or worse HES developed in 18 (60.0%) of 30 control patients and in 18 (60.0%) of 30 pyridoxine patients. The cumulative dose of capecitabine to grade 2 or worse HFS was not different between the two groups.

CONCLUSIONS

Pyridoxine is not effective in prevention of capecitabine-associated HFS.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial

Language

eng

PubMed ID

26158157

Citation

Ota, Mitsuyoshi, et al. "The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients With Adjuvant Chemotherapy Using Capecitabine: a Randomized Study." Hepato-gastroenterology, vol. 61, no. 132, 2014, pp. 1008-13.
Ota M, Tatsumi K, Suwa H, et al. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. Hepatogastroenterology. 2014;61(132):1008-13.
Ota, M., Tatsumi, K., Suwa, H., Watanabe, J., Watanabe, K., Osada, S., ... Endo, I. (2014). The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. Hepato-gastroenterology, 61(132), pp. 1008-13.
Ota M, et al. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients With Adjuvant Chemotherapy Using Capecitabine: a Randomized Study. Hepatogastroenterology. 2014;61(132):1008-13. PubMed PMID: 26158157.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study. AU - Ota,Mitsuyoshi, AU - Tatsumi,Kenji, AU - Suwa,Hirokazu, AU - Watanabe,Jun, AU - Watanabe,Kazuteru, AU - Osada,Shunichi, AU - Tanaka,Kuniya, AU - Shoichi,Fujii, AU - Ichikawa,Yasushi, AU - Kunisaki,Chikara, AU - Endo,Itaru, PY - 2015/7/10/entrez PY - 2015/7/15/pubmed PY - 2015/8/13/medline SP - 1008 EP - 13 JF - Hepato-gastroenterology JO - Hepatogastroenterology VL - 61 IS - 132 N2 - UNLABELLED: BACKGROUND/Aims: To determine the effect of the pyridoxine for prevention of hand-foot syndrome in colorectal cancer patients with adjuvant chemotherapy using capecitabine. METHODOLOGY: Colorectal cancer patients scheduled for capecitabine chemotherapy as adjuvant setting were randomly assigned to with or without concurrent oral pyridoxine (60 mg/d) groups. Patients were monitored whether being a development of National Cancer Institute Common Toxicity Criteria grade 2 or worse HFS until chemotherapy ended. RESULTS: Sixty patients were enrolled in this study. Relative dose intensity was 89.5% in total. The median number of chemotherapy cycles to grade 2 or worse HFS was four in both groups. Grade 2 or worse HES developed in 18 (60.0%) of 30 control patients and in 18 (60.0%) of 30 pyridoxine patients. The cumulative dose of capecitabine to grade 2 or worse HFS was not different between the two groups. CONCLUSIONS: Pyridoxine is not effective in prevention of capecitabine-associated HFS. SN - 0172-6390 UR - https://www.unboundmedicine.com/medline/citation/26158157/The_Effect_of_Pyridoxine_for_Prevention_of_Hand_Foot_Syndrome_in_Colorectal_Cancer_Patients_with_Adjuvant_Chemotherapy_Using_Capecitabine:_A_Randomized_Study_ L2 - http://www.diseaseinfosearch.org/result/1746 DB - PRIME DP - Unbound Medicine ER -